Sign in Subscribe

targeted-therapy

A collection of 17 issues

KRAS G13C Inhibitor Reveals Unique Biology of Codon 13 Mutations

Skip to content The CRC Digest KRAS G13C Inhibitor Reveals Unique Biology of Codon 13 Mutations RMC-8839, a covalent KRAS G13C inhibitor, induced tumor regressions in selected xenograft models, but one-third of cell lines showed incomplete pathway suppression, revealing that codon 13-mutant RAS differs from other KRAS mutations with decreased

CDK4/6 inhibitor palbociclib targets β-catenin in KRAS-mutant tumors

Skip to content The CRC Digest CDK4/6 inhibitor palbociclib targets β-catenin in KRAS-mutant tumors Preclinical research identified palbociclib as an unexpected suppressor of β-catenin signaling that synergizes with KRAS or ERK5 inhibition in colorectal cancer models. (Journal of Translational Medicine) This content is informational only and does not constitute

CRC Research Finding

Skip to content The CRC Digest ◇ KRAS-mutant colorectal cancers show variable response to RAS inhibitors Preclinical research found that KRAS-mutant colorectal cancer models respond differently to RAS(ON) inhibitor RMC-7977 based on PI3K signaling and cyclin D1 expression patterns, with combined RAS and PI3K inhibition showing synergistic effects in some

MiR-31 as Predictive Biomarker for Cetuximab Response

Skip to content The CRC Digest MiR-31 as Predictive Biomarker for Cetuximab Response A systematic review evaluated microRNA-31 (miR-31-3p and miR-31-5p) as a potential predictive biomarker for cetuximab efficacy in metastatic CRC, even among RAS wild-type patients where response variability remains high. (Clin Transl Oncol) This content is informational only

CRC Research Finding

Skip to content The CRC Digest ▸ Cetuximab Maintenance Therapy Evaluated in Meta-Analysis A systematic review and meta-analysis assessed the efficacy and safety of cetuximab maintenance therapy in metastatic colorectal cancer, pooling data on progression-free survival, overall survival, and adverse effects through March 2026. (Front Pharmacol) This content is informational only

KRAS G13D-mutant metastatic rectal cancer achieves 16.6 months disease control with TAS-102 plus bevacizumab

Skip to content The CRC Digest KRAS G13D-mutant metastatic rectal cancer achieves 16.6 months disease control with TAS-102 plus bevacizumab A 57-year-old man with KRAS G13D-mutant metastatic rectal cancer and fluoropyrimidine intolerance achieved approximately 16.6 months of disease control with trifluridine/tipiracil plus bevacizumab integrated with liver-directed treatments,

Novel SOS1 Inhibitors Show Potent Activity Against KRAS-Driven CRC

Skip to content The CRC Digest Novel SOS1 Inhibitors Show Potent Activity Against KRAS-Driven CRC Highly potent and selective SOS1 inhibitors disrupted the SOS1-KRAS interaction, inhibited nucleotide exchange in wild-type and multiple KRAS variants, and showed submicromolar anti-proliferative activity in colorectal cancer cells. (J Med Chem) This content is informational

BRAF V600E triplet regimen advances in phase 3 trial

Skip to content The CRC Digest BRAF V600E triplet regimen advances in phase 3 trial BREAKWATER Cohort 3 evaluated encorafenib + cetuximab + FOLFIRI versus FOLFIRI ± bevacizumab in previously untreated BRAF V600E-mutant mCRC, with primary endpoint of objective response rate and key secondary endpoint of progression-free survival. (Annals of Oncology) This content

Phase 2 trial tests fruquintinib plus chemotherapy in RAS-mutant CRC

Skip to content The CRC Digest ◆ TRIAL DATA Phase 2 trial tests fruquintinib plus chemotherapy in RAS-mutant CRC — Journal of Clinical Oncology A multicenter, open-label phase 2 study evaluated fruquintinib (a targeted therapy) combined with FOLFIRI or mFOLFOX6 chemotherapy as second-line treatment for patients with RAS-mutant metastatic colorectal cancer. RAS

Prior anti-EGFR therapy affects HER2-targeted treatment outcomes

Skip to content The CRC Digest ▸ TREATMENT Prior anti-EGFR therapy affects HER2-targeted treatment outcomes — ESMO Open An integrated analysis of the TRIUMPH and MyPathway studies examined how prior treatment with anti-EGFR (epidermal growth factor receptor) therapy affects the effectiveness of pertuzumab plus trastuzumab in HER2-amplified metastatic colorectal cancer. The study